Weight-Loss shot may help obese women beat uterine cancer without surgery

NCT ID NCT07349641

First seen Jan 26, 2026 · Last updated May 25, 2026 · Updated 19 times

Summary

This study tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel IUD (a hormone-releasing device placed in the uterus) can eliminate cancer or precancerous cells in overweight or obese women with early-stage endometrial cancer or a precancerous condition. About 55 women will receive both treatments for 26 weeks. The goal is to see if the combination works better than the IUD alone, potentially offering a non-surgical option for those who want to preserve their uterus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ATYPICAL HYPERPLASIA/ENDOMETRIOID INTRAEPITHELIAL NEOPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Lyndon Baines Johnson General Hospital

    Houston, Texas, 77026-1967, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Northwestern University

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.